Boundless Bio is a biotechnology company developing ecDNA-directed therapies (ecDTx) to improve and extend the lives of patients with oncogene amplified cancers.

Howard Chang

Jonathan Lim

Keith Lenden

Benjamin Cravatt

Boundless Bio

Boundless Bio is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence.

When DNA in cancer cells comes off chromosomes, “extrachromosomal DNA (ecDNA),” it becomes unbound and unwound, thereby enabling numerous copies of cancer-causing genes,  driving cancer cells to grow and allowing them to resist treatment.  At Boundless Bio, we are counterattacking this ecDNA phenomenon with boundless innovation and boundless energy to develop powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive.

Our Culture:

At Boundless, you’ll experience what it means to be out in front of the wave. 
Our unprecedented science takes us to new shores, and our team navigates the best breaks. We’re leaders in our field, and we’re dedicated to the cause of understanding and treating intractable cancers.

Every employee at Boundless makes an unbridled impact on our capabilities and our culture. We’ll help you expand your abilities and defy your bounds by providing meaningful work and unbounded opportunities. Career development is essential at Boundless. 

We’re all in on this fight against cancer– collaboration is requisite to our success. We have a team of people who ask, offer, and accept help without regard for ego. We know that receiving support is energizing, and giving help is fulfilling. We are inspired by the patients who are reliant upon our success. 

At Boundless, we’re all in. We are unbound by convention, bound to save lives. 


Career Inquiries
careers@boundlessbio.com

General Information Inquiries
info@boundlessbio.com

Wellington Management

GT Healthcare Capital Partners

Alexandria Venture Investments

Surveyor Capital

Vertex Ventures

Boxer Capital

Fidelity Management and Research Company

Nextech Invest

PFM Health Sciences

RA Capital Management

Redmile Group

Fidelity

Logos Capital

City Hill Ventures

ARCH Venture Partners

Piper Heartland Healthcare Capital

Today’s bell ringing ceremony was extra special for Boundless Bio, celebrating alongside inspiring students from DREAM New York Charter High School. Thank you Life Science Cares San Diego and Life Science Cares New York for bringing us together. These stellar students helped us ring in our big day all while learning first-hand about the #IPO process and stock market. Thank you for joining us!

A $BOLD step forward for Boundless and patients with oncogene amplified cancer. Today, we celebrate our #IPO at Nasdaq during the opening bell ringing ceremony. 
 
We are energized and committed to our pursuit of novel, potentially life-improving treatment options for patients with oncogene amplified cancers. Thank you to our team, partners, investors and supporters – here’s to our next chapter!

Working with such amazing teammates every day is a wonderful honor. On #InternationalWomensDay and every day, we’re deeply grateful for the commitment and expertise the incredible women of Boundless Bio bring to the table.

Today we’re featuring Claire Kuelbs, one of our Sr. Research Associate’s story in her “Boundless Bio.” Claire fell in love with biology in high school and hasn’t looked back since. By taking advantage of opportunities throughout her career, she’s been able to combine her love of biology and working with people as a mentor. Her advice to other women? “Love what you do and just go do it. There are so many opportunities out there now, so just believe in yourself and go get it.”

Claire represents many successful and courageous women at Boundless and worldwide who shape our lives with their charisma and contributions. Thank you for sharing! 

We’re eager to share that we will be at #AACR24 with multiple poster presentations April 5-10 in San Diego, CA. Our team is looking forward to engaging with other industry leaders and discussing our oral CHK1 inhibitor, BBI-355, as well as #ecDNA-driven cancer. We will be presenting Sunday, Monday and Tuesday. See below for more details. https://lnkd.in/e7GmMG-x

To our BoundTowners: Thank you! 
 
Our #EmployeeAppreciationDay breakfast has been an annual tradition to show deep gratitude for our team. Leaders took to the griddle to flip pancakes for everyone, creating a delightful morning of laughter and connection. Here's to another year of teamwork and success.

Metric
Company Name	Boundless Bio
Symbol
MSH ID	COM:BOUNDLESSBIO
Market	PRIVATE
Sector	9
Industry	Healthcare & Health Services
Country	US
Stage
Employee Count	80
Website	boundlessbio.com
LinkedIn	boundlessbio
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:BOUNDLESSBIO

Boundless Bio

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue